We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.
- Authors
Patel, Jyoti D; Paz-Ares, Luis; Zinner, Ralph G; Barlesi, Fabrice; Koustenis, Andrew G; Obasaju, Coleman K
- Abstract
Although lung cancer prognosis remains poor for most patients, treatments developed in the past 2 decades have extended survival for many. For those with disease that responded to or those with stable disease after receipt of platinum-based chemotherapy, maintenance regimens enable continued targeting of tumors beyond the induction phase, which is limited by toxicity. This overview summarizes completed phase 3 trials of pemetrexed continuation maintenance treatment in nonsquamous, non-small-cell lung cancer with a focus on 2-year survival, and highlights similar ongoing trials. Some studies showed survival benefits of pemetrexed maintenance treatment versus control arms, with the potential for added benefit when combined with bevacizumab. Two-year survival rates underscore the value of maintenance therapy and suggest progress toward a clinical goal of managing non-small-cell lung cancer as a treatable chronic disease.
- Publication
Clinical Lung Cancer, 2018, Vol 19, Issue 6, pe823
- ISSN
1525-7304
- Publication type
journal article
- DOI
10.1016/j.cllc.2018.05.013